The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of toxicity of A oligomers. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of Alzheimer's Disease. The invention also relates to methods of medical treatment.

Described are anti-doppel antibody-drug conjugates, compositions comprising them, and related methods of treating doppel-associated diseases and conditions, including cancer.

A method and system to identify an epitope unique to a misfolded form of a protein is provided. Sets of one or more amino acid residues are selected from a model representing the structure of the protein; the free energy of unfolding of each set is determined; and the epitope is identified from the sets having a total probability of unfolding above a minimum probability or a free energy of unfolding below a minimum energy. In other aspects, the invention provides for the use of epitopes identified by the epitope prediction methods, and related antibodies, to diagnose and treat disease and to screen samples for the presence of such epitopes.

The present disclosure provides antibodies and antigen-binding fragments capable of binding PrP.sup.c. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.

The present invention is directed to an anti-prion monoclonal antibody and its use for the treatment of conditions associated with or mediated by proteins or peptides having a toxic oligomeric form. These conditions include, but are not limited to, Alzheimer's disease, frontotemporal dementias, traumatic brain injury, and chronic traumatic encephalopathy.

A monoclonal antibody against human PrPc protein capable of reducing the expression level of transcription factor Twist1 in a targeting mode and inducing macrophage and NK cells to target to rectal cancer tumor cells. The combined drug therapy with the antibody and cetuximab also exhibits inhibitory effect on tumor better than administration of the antibody or cetuximab alone.

The present disclosure relates generally to polypeptides, which may be used of the treatment of neurological diseases or disorders.

The present disclosure provides antibodies and antigen-binding fragments capable of binding PrP.sup.C. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.

Provided herein are an exogenous antibody that binds selectively to a misfolded form of human FasR, and methods and uses for said antibody. Specifically disclosed is the antibody designated AMF 3a-118 which selectively binds the peptide represented by LHHDGQFCH (SEQ ID NO:2) and the antibody designated AMF 3d-19 which selectively binds the peptide represented by NSTVCEH (SEQ ID NO:5).

Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.